Blaine Mooers to Lung Neoplasms
This is a "connection" page, showing publications Blaine Mooers has written about Lung Neoplasms.
Connection Strength
0.455
-
Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 12; 7(12):1074-1088.
Score: 0.146
-
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
Score: 0.141
-
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
Score: 0.138
-
Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol. 2018 09; 175(17):3504-3515.
Score: 0.029